Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, and mAbsolve, developers of a novel Fc silencing variant, today announced a licensing deal for mAbsolve’s Fc silencing technology. The agreement provides Absolute Antibody clients with easy license-free access to the new STR Fc silencing platform for antibody research and development, while ensuring … Read more

evitria AG, the market-leading transient CHO expression service provider, today announces the closing of a license agreement with mAbsolve Ltd for mAbsolve’s proprietary STR technology. Under the agreement, evitria will supply their global client base with antibodies bearing STR silencing modifications. These clients will then be able to evaluate the STR technology in their experiments … Read more

This quarter saw our publication on the STR silencing technology accepted and published in PLOS ONE (see here). It has been exciting to see our work go through the stringent peer-review process at PLOS ONE and we have continued to receive excellent feedback as word of our work spreads further. To this end we have … Read more

We are delighted to announce that our novel STR silencing technology has been recently published in the peer reviewed and open access journal PLoS ONE. This is available to download by clicking on the image below. We would like to thank all our partners that contributed to this work: Absolute Antibody, ProImmune, Antibody Analytics, Reading … Read more

The STR antibody technology developed by mAbsolve for truly silenced antibodies has been licensed to ONA Therapeutics for evaluation in their pipeline of therapeutic antibodies for advanced cancer. Dr. Valerie Vanhooren, CEO of ONA Therapeutics, said: We are delighted to be working with the highly experienced mAbsolve team. Having access to the novel Fc silencing … Read more